Hologic delivered Q2 2025 results that met revenue and adjusted EPS guidance, despite a GAAP net loss driven by significant intangible asset impairment charges.
Revenue came in at $1,005,300,000, slightly exceeding guidance.
GAAP EPS was a loss of $0.08 due to $220.9 million in impairment charges.
Non-GAAP EPS was $1.03, reaching the high end of guidance.
Diagnostics and skeletal health segments performed strongly, offsetting declines in breast health.
Hologic maintained its full-year revenue guidance but lowered its EPS expectations due to tariffs and geopolitical uncertainty.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance